Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.

Abstract

OBJECTIVE:

It was the aim of this study to analyze the clinical value of the determination of serum S-100beta protein in high-risk melanoma patients.

PATIENTS AND METHODS:

Patients were tested for serum S-100beta protein by luminoimmunometric assay after melanoma surgical excision, before starting interferon-alpha2b and every 3 months thereafter, until treatment was completed.

RESULTS:

Ninety-seven patients were included in the study. Median follow-up was 62.9 months (range 32.7-87.4). High baseline S-100beta levels were associated with positive lymph node status (p = 0.02). High S-100beta levels (during therapy) showed a relation with positive lymph node status (p = 0.014), number of positive lymph nodes (p = 0.01), macroscopic lymph node involvement (p = 0.002) and second melanoma diagnosis at study entry (p = 0.001). By univariate analysis, high baseline S-100beta levels were associated with disease-free survival (p = 0.004) and overall survival (p = 0.0007). Similarly, high S-100beta levels during therapy were associated with disease-free survival (p < 0.0001) and overall survival (p < 0.0001). In the multivariate analysis, high S-100beta levels during therapy (hazard ratio 1.017, 95% CI 1.008-1.026; p < 0.0001) and high baseline S-100beta levels (hazard ratio 3.31, 95% CI 1.10-9.89; p = 0.032) were independent prognostic factors for overall survival when compared with low levels while on therapy and low baseline S-100beta levels, respectively.

CONCLUSIONS:

These results provide evidence of the clinical usefulness of serum S-100beta level determination in high-risk melanoma patients. S-100beta serum determination should be considered to be included in clinical trials that test adjuvant therapies in melanoma patients.

• Authors: Josep Domingo-Domènech, Teresa Castel, Josep Maria Auge, Xabier Adrian Garcia-Albeniz, Carles Conill, Susana Puig, Ramon Vilella, Jose Matas, Josep Malvehy, Pere Gascón, Begoña Mellado, Rafael Molina
• Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) Vol. 28 Issue 5 Pg. 264-72 ( 2007) ISSN: 1423-0380 [Electronic] Netherlands
• PMID: 17962723 (Publication Type: Journal Article)
• Copyright: Copyright (c) 2007 S. Karger AG, Basel.

Chemical References

• Biomarkers, Tumor
• Immunologic Factors
• Interferon alpha-2
• Interferon-alpha
• Nerve Growth Factors
• Recombinant Proteins
• S100 Calcium Binding Protein beta Subunit
• S100 Proteins

Topics

• Adult
• Aged
• Biomarkers, Tumor (blood)
• Combined Modality Therapy
• Disease-Free Survival
• Female
• Humans
• Immunologic Factors (therapeutic use)
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Kaplan-Meier Estimate
• Male
• Melanoma (blood, drug therapy, mortality, pathology, surgery)
• Middle Aged
• Neoplasm Staging
• Nerve Growth Factors (blood)
• Prognosis
• Prospective Studies
• Recombinant Proteins
• Risk
• S100 Calcium Binding Protein beta Subunit
• S100 Proteins (blood)
• Skin Neoplasms (blood, drug therapy, mortality, pathology, surgery)
• Survival Analysis
• Treatment Outcome